OTCPK:AROS.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., develops and distributes spinal implant products in Canada. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Aurora Spine's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AROS.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-6.3%

AROS.F

1.1%

US Medical Equipment

1.0%

US Market


1 Year Return

-38.4%

AROS.F

15.4%

US Medical Equipment

13.6%

US Market

Return vs Industry: AROS.F underperformed the US Medical Equipment industry which returned 16.2% over the past year.

Return vs Market: AROS.F underperformed the US Market which returned 14.2% over the past year.


Shareholder returns

AROS.FIndustryMarket
7 Day-6.3%1.1%1.0%
30 Day-11.2%1.5%-0.4%
90 Day23.4%12.0%8.9%
1 Year-38.4%-38.4%16.4%15.4%16.2%13.6%
3 Year134.2%134.2%73.3%68.8%40.2%30.8%
5 Year-16.3%-16.3%149.6%130.6%89.6%68.2%

Price Volatility Vs. Market

How volatile is Aurora Spine's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aurora Spine undervalued compared to its fair value and its price relative to the market?

3.74x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: AROS.F ($0.19) is trading above our estimate of fair value ($0.1)

Significantly Below Fair Value: AROS.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: AROS.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: AROS.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AROS.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AROS.F is good value based on its PB Ratio (3.7x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Aurora Spine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aurora Spine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Aurora Spine performed over the past 5 years?

35.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AROS.F is currently unprofitable.

Growing Profit Margin: AROS.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AROS.F is unprofitable, but has reduced losses over the past 5 years at a rate of 35.3% per year.

Accelerating Growth: Unable to compare AROS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AROS.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: AROS.F has a negative Return on Equity (-52.31%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aurora Spine's financial position?


Financial Position Analysis

Short Term Liabilities: AROS.F's short term assets ($5.4M) exceed its short term liabilities ($2.1M).

Long Term Liabilities: AROS.F's short term assets ($5.4M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: AROS.F's debt to equity ratio (73.5%) is considered high.

Reducing Debt: Insufficient data to determine if AROS.F's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable AROS.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: AROS.F is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 53.9% per year.


Next Steps

Dividend

What is Aurora Spine current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AROS.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AROS.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AROS.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AROS.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AROS.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.2yrs

Average board tenure


CEO

Trent Northcutt (53 yo)

8.58yrs

Tenure

US$143,042

Compensation

Mr. Trent J. Northcutt is the Chief Executive Officer and President at Aurora Spine Corporation since February 2012. He is a Founder of Aurora Spine Corporation. Mr. Northcutt served as Vice President at S ...


CEO Compensation Analysis

Compensation vs Market: Trent's total compensation ($USD143.04K) is below average for companies of similar size in the US market ($USD594.44K).

Compensation vs Earnings: Trent's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Trent Northcutt
Founder8.58yrsUS$143.04k9.35%
$ 1.0m
David Rosenkrantz
Independent Chairman4.92yrsUS$20.28k15.95%
$ 1.7m
Tracy Graf
Independent Director7.17yrsUS$2.02k0.13%
$ 13.8k
Joseph MacLellan
Independent Director7.17yrsUS$1.98k0.71%
$ 77.6k
James Snow
Independent Director7.17yrsUS$2.50k1.98%
$ 216.4k
Michael Seid
Independent Director7.17yrsUS$1.73k0.18%
$ 19.2k

7.2yrs

Average Tenure

55.5yo

Average Age

Experienced Board: AROS.F's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.3%.


Top Shareholders

Company Information

Aurora Spine Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aurora Spine Corporation
  • Ticker: AROS.F
  • Exchange: OTCPK
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$14.407m
  • Listing Market Cap: CA$10.942m
  • Shares outstanding: 55.41m
  • Website: https://www.aurora-spine.com

Location

  • Aurora Spine Corporation
  • 20 Holly Street
  • Suite 300
  • Toronto
  • Ontario
  • M4S 3B1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ASGTSXV (TSX Venture Exchange)YesCommon SharesCACADSep 2013
AROS.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2013

Biography

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., develops and distributes spinal implant products in Canada. The company offers interspinous process lumbar fusion devices for patients ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 05:58
End of Day Share Price2020/09/16 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.